To identify lipid signals linked to retinal degeneration and assess the effects of restoring erucamide levels.
Approach:
Metabolomics Screening: Researchers conducted an unbiased high-resolution metabolomics screen in rodent models of retinal degeneration to identify candidate signals.
Lipid Delivery: Erucamide was packaged into organosilane-modified porous silicon nanoparticles for delivery into the eye.
Mechanistic Studies: Confocal imaging and gene-expression analysis were used to investigate the uptake of erucamide by retinal myeloid cells and its signaling mechanisms.
Key Findings:
Erucamide levels decrease as photoreceptors deteriorate in retinal degeneration models, including RCS rats and rd10 mice.
Erucamide is taken up by CD11b+ retinal myeloid cells, which are linked to vascular and neuronal support.
TMEM19 was identified as a candidate erucamide-binding protein, with its knockdown weakening the signaling response and retinal benefits.
Interpretation:
Erucamide may coordinate the retinal response to injury by engaging the surrounding environment rather than directly targeting photoreceptors.
Limitations:
The study primarily focused on rodent models, necessitating further testing in additional retinal disease models.
Conclusion:
The findings suggest a potential new pathway for treating degenerative retinal diseases by modulating existing lipid signals, warranting further testing in additional retinal disease models.
US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.
